1. Portada
  2. Transferencia & Resultados
  3. Publicaciones sobre COVID-19

Publicaciones sobre COVID-19

  • Comparative analysis of government management of crisis communication in Covid-19, mad cow and 11M attacks. Solana, Y. M.;  Garcia, T. M. Historia Y Comunicacion Social ; 26:61-73, 2021.
  • Article in Spanish | Web of Science | ID: covidwho-1154716
  • Incluido como referencia en la web de la OMS.
  • https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1154716?lang=en
  • Gortazar C., Rodriguez del Rio FJ., Dominguez L. y de la Fuente J. Host or pathogen-related factors in COVID-19 severity?. The Lancet. 396(10260):1396-1397. 2020. (L). ISSN: 0140-6736. DOI: 10.1016/S0140-6736(20)32215-7
  • Fernandez de Mera IG., Rodriguez del Rio FJ., de la Fuente J., Perez-Sancho M., Hervas D., Moreno I., Dominguez M., Dominguez L. y Gortazar C. Detection of environmental SARS-CoV-2 RNA in a high prevalence setting in Spain. Transboundary and Emerging Diseases. 1-6. 2020. (A). ISSN: 1865-1674. DOI: 10.1111/tbed.13817
  • Gortazar C., Barroso-Arevalo S., Ferreras-Colino E., Isla J., de la Fuente G., Rivera B., Dominguez L., de la Fuente J. y Sanchez-Vizcaino JM. Natural SARS-CoV-2 Infection in Kept Ferrets, Spain. Emerging Infectious Diseases. 27:7. 2021. (L). ISSN: 1080-6040. DOI: 10.3201/eid2707.210096
  • Barroso-Arevalo S., Rivera B., Dominguez L. y Sanchez-Vizcaino JM. First Detection of SARS-CoV-2 B.1.1.7 Variant of Concern in an Asymptomatic Dog in Spain. Viruses-Basel. 13(7):1379. 2021. (A). ISSN: 1999-4915. DOI: 10.3390/v13071379
  • Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Sampath V et al. Allergy. 2021 76,1640-1660. doi: 10.1111/all.14840.
  • Management of anaphylaxis due to COVID-19 vaccines in the elderly.
  • Bousquet J. Et al. Allergy. 2021 Apr 2:10.1111/all.14838. doi: 10.1111/all.14838.
  • COVID-19 pandemic and allergen immunotherapy-an EAACI survey.
  • Pfaar O, et al. Allergy. 2021 Mar 2:10.1111/all.14793. doi: 10.1111/all.14793.
  • EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, Jutel M, Nadeau KC, Palomares O, Rabin RL, Riggioni C, Vieths S, Agache I, Shamji MH. Allergy. 2021 Jun;76(6):1629-1639. doi: 10.1111/all.14739.
  • Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H.
  • Klimek L. Et al. Allergol Select. 2020 Sep 7;4:53-68. doi: 10.5414/ALX02166E.
  • Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Sokolowska M. Et al. Allergy. 2020 Oct;75(10):2445-2476. doi: 10.1111/all.14462.
  • Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c: Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)B, der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI)D, der Luxemburgischen Gesellschaft für Allergologie und Immunologie (LGAI)E, der Österreichischen Gesellschaft für Pneumologie (ÖGP)F in Kooperation mit der deutschen, österreichischen, und schweizerischen ARIA-GruppeG und der Europäischen Akademie für Allergologie und Klinische Immunologie (EAACI)H. Klimek L. et al. Allergo J. 2020;29(4):14-27. doi: 10.1007/s15007-020-2553-y.
  • COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.
  • Pfaar O. et al. Allergy. 2021 Mar;76(3):648-676. doi:10.1111/all.14453.
  • Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Vultaggio A. et al. Allergy. 2020 Nov;75(11):2764-2774. doi: 10.1111/all.14407.
  • Sterilization of Biological Weapons in Technical Clothing and Sensitive Material by High-Pressure CO2 and Water, L. Calvo, J. Casas, Ind. Eng. Chem. Res. 57 (2018) 4680–4687. doi:10.1021/acs.iecr.7b04794.
  • Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
  • Palanques-Pastor T. et al. Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
  • Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. López-Medrano F. et al. Int J Infect Dis. 2021, 105:487-494. doi: 10.1016/j.ijid.2021.02.099.
  • Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. de la Calle C et al. Int J Infect Dis. 2021 105:319-325. doi: 10.1016/j.ijid.2021.02.041.
  • Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Rodríguez Rodríguez M. et al. Int J Lab Hematol. 2021, 43:O152-O155. doi: 10.1111/ijlh.13476.
  • Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Chari A et al. Blood. 2020 136:3033-3040. doi: 10.1182/blood.2020008150.
  • Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Martínez-López J et al. Blood Cancer J. 2020 10:103. doi: 10.1038/s41408-020-00372-5.
  • Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. García-Suárez J et al. J Hematol Oncol. 2020 13:133. doi: 10.1186/s13045-020-00970-7.
  • Thrombosis and antiphospholipid antibodies in patients with SARS-COV-2 infection (COVID-19). Gutiérrez López de Ocáriz X. et al. Int J Lab Hematol. 2020 42:e280-e282. doi: 10.1111/ijlh.13320.
  • Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. Snyder TM et al. medRxiv. 2020 Sep 17:2020.07.31.20165647. doi: 10.1101/2020.07.31.20165647. Preprint.
  • A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. Nolan S et al. Res Sq. 2020 Aug 4:rs.3.rs-51964. doi: 10.21203/rs.3.rs-51964/v1. Preprint.
  • IL-6-based mortality risk model for hospitalized patients with COVID-19. Laguna-Goya R et al. J Allergy Clin Immunol. 2020 146:799-807.e9. doi: 10.1016/j.jaci.2020.07.009.
  • Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Sanchez-Pina JM et al. Eur J Haematol. 2020 105:597-607. doi: 10.1111/ejh.13493.
  • Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. Fernández-Ruiz M et al. J Med Virol. 2021 93:831-842. doi: 10.1002/jmv.26308.
  • IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. Villegas C et al. Ann Hematol. 2020 99:2953-2956. doi: 10.1007/s00277-020-04160-w.
  • Determination of the characteristic inactivation fluence for SARS-CoV-2 under UV-C radiation considering light absorption in culture media. J.C. Martinez-Anton, A. Brun, D. Vázquez, S. Moreno, A. A. Fernández-Balbuena, J. Alda. Scientific Reports 2021 11:15293 doi: 10.1038/s41598-021-94648-w.